Cytokinetics insider trade: Dr. Malik nets $37.47 on 2k-share sale

Rhea-AI Filing Summary

EVP R&D Dr. Fady I. Malik reported one option exercise and a matching open-market sale on 22 Jul 2025. He exercised 2,000 non-qualified options at $10.60, receiving 2,000 CYTK shares (Code M), then sold the same 2,000 shares at $37.47 (Code S). Net share count declined slightly from 142,610 to 140,610 shares, all held directly. Malik still holds 13,105 unexercised options with a $10.60 strike expiring 28 Feb 2027.

The trade represents roughly 1.4% of his direct equity position and appears to be a routine liquidity event following option exercise rather than a wholesale reduction. No other executives are involved and there are no disclosures affecting company fundamentals.

Positive

• Executive retains sizable stake (140,610 shares) indicating continued alignment with shareholder interests.
• Option exercise suggests confidence in long-term value sufficient to convert in-the-money options ahead of 2027 expiry.

Negative

• Open-market sale of 2,000 shares could be interpreted as modest insider profit-taking.

Insights

Securities Analyst

TL;DR: Small insider sale after option exercise, immaterial to ownership or valuation.

The transaction pairs a 2,000-share option exercise at $10.60 with an immediate sale at $37.47, locking in ~ $27/share gain. Post-trade ownership of 140,610 shares plus 13,105 options keeps Malik highly aligned. Volume is minor versus CYTK’s 94 m shares outstanding and does not signal strategic shift. I view the filing as routine housekeeping, neutral for investors.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Malik Fady Ibraham

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP Research & Development

3. Date of Earliest Transaction (Month/Day/Year)
07/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/22/2025		M		2,000	A	$10.6	142,610	D
Common Stock	07/22/2025		S		2,000	D	$37.47	140,610	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (Right to Buy)	$10.6	07/22/2025		M			2,000	03/28/2017	02/28/2027	Common Stock	2,000	$0	13,105	D

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Dr. Malik	07/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many CYTK shares did EVP Fady Malik sell on 22 Jul 2025?

He sold 2,000 common shares at $37.47 each.

What was the exercise price of the options converted?

The non-qualified options were exercised at $10.60 per share.

How many CYTK shares does the executive still own after the transaction?

Dr. Malik directly owns 140,610 shares following the sale.

Does the executive retain additional unexercised options?

Yes, he holds 13,105 options expiring 28 Feb 2027.

Is this Form 4 filing considered material to Cytokinetics shareholders?

Given the small size (≈1.4% of his holdings), analysts generally view it as immaterial to CYTK’s fundamentals.